23 November 2023
EMA/481574/2023
EMEA/H/C/005039

Public statement

Ivozall (clofarabine)

Withdrawal of the marketing authorisation in the European Union

On 18 October 2023, the European Commission withdrew the marketing authorisation for Ivozall (clofarabine) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, ORPHELIA Pharma SAS, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Ivozall was granted marketing authorisation in the EU on 14 November 2019 for treatment of acute lymphoblastic leukaemia. The marketing authorisation was initially valid for a 5-year period. The product had not been marketed in the EU since 2022.

Ivozall is a generic medicine of Evoltra. There are other generic medicinal products of Evoltra authorised and marketed in the EU.

The European Public Assessment Report (EPAR) for Ivozall will be updated to indicate that the marketing authorisation is no longer valid.

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union